Bristol Myers faces billion-dollar claim over cancer drug
An ICC panel in New York is hearing a US$1.5 billion claim against US pharmaceuticals group Bristol Myers Squibb over the supply of a cancer therapy drug that was blocked by Chinese regulators.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.